Actavis PLC (ACT.N)

ACT.N on New York Stock Exchange

241.81USD
19 Sep 2014
Price Change (% chg)

$3.88 (+1.63%)
Prev Close
$237.93
Open
$239.83
Day's High
$245.50
Day's Low
$236.53
Volume
933,382
Avg. Vol
408,861
52-wk High
$245.50
52-wk Low
$135.50

ACT.N

Chart for ACT.N

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.36
Market Cap (Mil.): $63,900.88
Shares Outstanding (Mil.): 264.26
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): 518.10 32.84 33.70
EPS (TTM): 0.47 -- --
ROI: 0.38 18.11 17.35
ROE: 0.94 18.82 18.21
Search Stocks

NY attorney general sues Actavis and Forest Labs over Alzheimer's drug

- The attorney general of New York filed a lawsuit against Actavis Plc and its subsidiary to stop the companies from discontinuing its Alzheimer's drug, alleging that they were trying to maintain a monopoly position illegally.

16 Sep 2014

NY attorney general sues Actavis and Forest Labs over Alzheimer's drug

Sept 15 - The attorney general of New York filed a lawsuit against Actavis Plc and its subsidiary to stop the companies from discontinuing its Alzheimer's drug, alleging that they were trying to maintain a monopoly position illegally.

16 Sep 2014

Drugmaker Actavis posts 34 pct rise in revenue

Aug 5 - Generic drug maker Actavis Plc's quarterly revenue rose 34 percent due to strong growth in its North America business.

05 Aug 2014

UPDATE 3-AstraZeneca buys Almirall lung drugs for up to $2.1 billion

* Initial $875 mln payout, up to $1.22 bln more if goals hit

30 Jul 2014

U.S. allows Actavis Plc's purchase of Forest Labs with conditions

WASHINGTON - Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.

01 Jul 2014

UPDATE 1-U.S. allows Actavis Plc's purchase of Forest Labs with conditions

(Adds details of drugs to be divested, share price, other pharma deals)

01 Jul 2014

U.S. allows Actavis Plc's purchase of Forest Labs with conditions

WASHINGTON, June 30 - Pharmaceutical company Actavis Plc has won U.S. approval to buy Forest Laboratories on condition that it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.

01 Jul 2014

Acorda's multiple sclerosis drug faces generic threat

June 26 - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra.

26 Jun 2014

Forest antidepressant Viibryd succeeds in anxiety disorder trials

June 23 - Forest Laboratories Inc, which is being acquired by generic drugmaker Actavis Plc, said on Monday that its antidepressant Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, according to data from three late-stage studies.

24 Jun 2014

BRIEF-U.S. appeals court rules for Novartis, Actavis, Apotex and against Allergan, Duke over patents related to eyelash growth

June 10 - Novartis AG : * Actavis PLC apotex inc win reversal of lower court ruling regarding

10 Jun 2014

Earnings vs. Estimates

Search Stocks